Salvianolate (SAL) is a prescribed medicine from the Chinese herb Danshen (Salvia miltiorrhiza Bunge). It has been widely used in treatment of coronary and other diseases with significant effects. The in vitro antimicrobial activities of SAL against infectious pathogens were assayed and its combined effects on 10 clinical isolates of SCCmec III type methicillin-resistant Staphylococcus aureus (MRSA) with ten antibiotics were evaluated. Susceptibility to each agent alone was tested using a broth microdilution method, and the chequerboard and time-kill experiments were used for the combined activities. The results showed MIC was 128e256 mg/L for SAL used alone against MRSA. Significant synergies were observed for SAL/ Ampicillin (Fosfomycin, Erythromycin, Piperacillin-tazobactam or Clindamycin) combination against over half of the isolates, with their MICs reduced by times of dilution (TOD) to 4e32 (FICIs 0.375e0.5), respectively. SAL/AMP combination showed the best combined effect of synergy on bacteriostatic and bactericidal activities, while SAL/AMK combination reversed the resistance of MRSA to AMK. The results demonstrated that SAL enhanced widely the in vitro anti-MRSA efficacy of the ten antibacterial agents, which had potential for combinatory therapy of patients infected with MRSA and warrants further investigations.
Introduction
Since the clinical isolate of methicillin-resistant Staphylococcus aureus (MRSA) was first reported in 1961, its current incidence is still high worldwide. MRSA could be amount to over 50% strains of all S. aureus in clinical infected patients, leading to increased morbidity and mortality, length of stay and healthcare burden (1, 2) . MRSA is resistant not only to b-lactams, but also to macrolides, clindamycin, quinolones and other antibacterial agents. MRSA has become one of the important pathogens in nosocomial patients, mostly causes infections of respiratory tract, burns, surgical site and bloodstream. The elderly patients are one group of the main risk individuals (3) . MRSA infections often become the fatal pathogeny among patients with multiple organ malfunctions or tumors. Although vancomycin is still one of the most effective anti-MRSA agent, it has a lot of adverse effects such as hypotension, phlebitis, nephrotoxicity, ototoxicity, hypersensitivity reactions, red man syndrome, neutropenia, chills, fever and interstitial nephritis (4) . The emergence of decreased vancomycin susceptibility and even resistant strains in MRSA has exhibited a significant clinical problem as well (5) . Therefore, new treatment strategies to cope with MRSA infections and to alleviate selection pressure of MRSA on the current anti-MRSA agents are inevitably needed.
Salvianolate (SAL) is a prescribed medicine derived from Danshen's principal active constituent Salvianolic acid B (6). It contains mainly Magnesium salvianolic acid B (!85%, Fig. 1 ) and other phenolic acids ( 15%) (7, 8) . Danshen is originated from the well-known Chinese herb Salvia miltiorrhiza Bunge (Labiatae) which has the function of promoting blood circulation (9, 10) . Both SAL and Danshen has been widely used in the treatment of cardiovascular and cerebrovascular diseases (6, 10) . A recent report demonstrated that Salvianolic acid B could protect against acetaminophen hepatotoxicity (11) . However, no detailed evaluation of SAL on methicillin-resistant S. aureus (MRSA) has been reported. Therefore, we herein present the report which deals with in vitro antibacterial and synergistic effects of SAL on conventional antibacterial agents against clinical isolates of MRSA.
Materials and methods

Bacterial strains and culture media
MRSA strains (ten isolates with SCCmec III genotype) were isolated and identified from the clinical sample of patients in Kunming General Hospital as previous reports (12e14). ATCC 25923 was used as the control strain. Standard MuellereHinton agar and broth (MHA and MHB, Tianhe Microbial Agents Co., Hangzhou, China) were used as bacterial culture media.
Antibacterial agents
SAL and ten antibacterial agents represented different conventional types were purchased from the manufacturers, i.e. Salvianolate (SAL (contains !85% magnesium salvianolic acid B), Shanghai Greenvalley Pharmaceutical Co., Ltd, Shanghai, China), and Ampicillin (AMP, North China Pharmaceutical Co., Ltd, Shijiazhuang, China), Ceftazidime (CAZ, Baiyunshan Tianxin Pharmaceutical Co., Ltd, Guangzhou, China), Cefazolin (CFZ, Harbin Pharmaceutical Co., Ltd, Harbin, China), Clindamycin (CLI, Lifeshine Pharmaceutical Co., Ltd, Beijing, China), Cefoperazone-sulbactam, Erythromycin, Fosfomycin and Piperacillin-tazobactam (CPS, ERY, FOS and PTZ, Hunan Central South Kelun Pharmaceutical Co., Ltd, Changsha, China). Amikacin (AMK, Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.); Levofloxacin (LEV, Yangzhijiang Pharmaceutical Co., Ltd, Taizhou, China). Vancomycin (VAN) (Eli Lilly Japan K. K., Seishin Laboratories) was used as the positive control agent. Cefoxitin disks were purchased from Tiantan biological products Co., Ltd (Beijing, China). 
Synergy testing of SAL in combination with the antibacterial agents against MRSA
Potential anti-MRSA synergy of SAL in combination with the ten antibacterial agents against MRSA was measured by fractional inhibitory concentration (FIC) indices (FICI) with chequerboard method and by time-killing curves as previously reported (17, 18) . The FIC of the combination was calculated through dividing the MIC of the SAL/antibacterial agent combined by the MIC of SAL or the antibacterial agent alone, and the FICI was obtained by adding the FIC of SAL and that of an antibacterial agent. The FICI results were interpreted as follows: FICI 0.5, synergy; 0.5 < FICI 1, additivity; and 1 < FICI 2, indifference (or no effect) and FICI >2, antagonism (17) . In the killing curves, synergy was defined as !2 log 10 CFU/mL increase in killing at 24 h with the combination in comparison with the killing by the most active single drug (△Log 10 CFU/mL at 24 h, i.e. △LC 24 ). Additivity was defined as a 1e2 log 10 CFU/mL increase in kill with the combination in comparison with the most active single agent. Indifference was defined as ±1 log 10 CFU/mL killing or growth. Combinations that resulted in >1 log 10 CFU/mL bacterial growth in comparison with the least active single agent were considered to represent antagonism (18) . All experiments were performed in triplicate.
Results
Effects of SAL used alone against MRSA
The MICs (mg/L) of Salvianolate (SAL, Fig. 1 ) and the ten clinical antibacterial agents AMP, AMK, CAZ, CFZ, CLI, CPS, ERY, FOS, LEV and PTZ used alone against 10 clinical MRSA isolates of SCCmec III type are shown in Table 1 . SAL showed MIC 50 and MIC 90 of both 256 mg/L (n ¼ 10). Meanwhile, SAL used alone showed similar activity against standard Gram-positive S. aureus (methicillin-susceptible S. aureus, MSSA) by MIC/MBC at 128/256 mg/L.
Anti-MRSA potentiation of the agents by SAL
The combined anti-MRSA MICs of SAL with the ten antibacterial agents are shown in Table 2 Table 1 and values of 50% in Table 2 . The best TOD was 32 in the combinations of SAL with ERY, with MIC reducing from 2048 (Table 1) to 64 mg/L ( Table 2 ). All the ten combinations showed 2e8 isolates of synergy or additive effect in the 10 MRSA strains as presented in the right end sub-columns of Interactions in Table 2 . Table 3 shows results of the combined time-killing analysis of SAL with the ten antibacterial agents. In addition, three typical killing curves by combination of SAL with AMP, CLI and LEV at their MIC level are exemplified in Fig. 2 . All combinations appeared as not significantly bactericidal interactions as compared to the combined bacteriostatic effects (Tables 2 and 3 , Fig. 2 ). Only the combinations of SAL with AMP showed synergy and the five combinations with AMK, CAZ, CLI, ERY and FOS showed only additivity. The rest combinations showed indifference.
Discussion
In the present report, we performed in vitro assays the anti-MRSA potentials of SAL used alone and synergistic interactions of SAL in combination with conventionally used antibacterial agents in clinic. It revealed a broad spectrum of synergy or additivity effects when SAL was combined with clinical agents of different (also TOD and FICI) is presented as SAL to the left of "/" and an antibacterial agent to the right of "/". d n 0 : the number of strains showed the action. classes. All the combinations of SAL with the ten antibacterial agents showed positive interactions by various degrees. However, SAL showed very weak activity against Gram-negative clinical pathogens of Escherichia coli (ATCC25922 and ATCC35218) and Pseudomonas aeruginosa (ATCC27853), and the fungus of Candida albicans (ATCCY0109). All these pathogens showed MICs !2048 mg/L (data no shown).
SAL has been widely used for the treatment of cardiovascular and cerebrovascular diseases (6) . These effects of SAL, including Salvianolic acid B and other Danshen's components and Danshen itself are so far the predominant research topics in the previous reports (6e11, 19). Apart from Danshen's extracts and a lipidsoluble constituent Cryptotanshinone which have been studied of the antibacterial activities (including (synergistic) activity against MRSA), other active components in the extracts were not clarified (20e24). Neither SAL as well as Salvianolic acid B from Danshen have been investigated against MRSA. Therefore, the systematic evaluations of SAL antibacterial alone and its synergistic activities with conventional antibacterial agents against MRSA are so far for the first time to our best knowledge.
It is interestingly noted that AMK with MIC 50 of 32 mg/L alone showed intermediate susceptible against the MRSA isolates by the MIC Interpretive Criteria (25) (Table 1) . However, its MIC 50 reduced to 8 mg/L when it was combined with SAL, so the resistance of MRSA to AMK could be viewed as reversed in the combination of SAL/AMK, which is a promising result of potentiation of the anti-MRSA activity to be expected.
A previous report showed that the mechanism of synergy between epigallocatechin gallate (EGCG) and b-lactams such as AMP against MRSA was attributed to interference with the integrity of the cell wall through direct binding to peptidoglycan (26) . Similarly, another report also demonstrated that corilagin and tellimagrandin I could remarkably potentiate the activity of b-lactams against MRSA. The inactivation of PBPs, especially of PBP2 0 (PBP2a) and to some extent suppression of b-lactamase activity by corilagin or tellimagrandin I would make b-lactams restore their antibacterial effect on MRSA (22, 27) . As SAL, EGCG, corilagin and tellimagrandin all contain multi-hydroxyl groups within their structures and can be classified as polyphenols, the potentiation of b-lactams, especially of AMP by SAL might be ascribed to the same mechanisms.
For other b-lactams and antibacterial agents' types, mechanisms of potentiation might be varied and remained to be studied. As Table 1 shows and the previously reported, clinical MRSA strains is a multidrug resistant bad bug (28, 29) . It is continuing to cause severe worldwide clinical problems. The critical shortage of new antibacterial agents makes global researchers pay great attention to find novel effective candidates and new treatment ways (3, 30, 31) . While suffering from cardiovascular and cerebrovascular diseases, the secondary respiratory infections by MRSA often lead to death of elderly and immunocompromised patients. The new effects of SAL may play an additional role in preventing the patients from MRSA infection. Given the known indications and our new finding of SAL potentiation effects of antibacterial agents against MRSA, it might be especially beneficial to the patients with both vascular diseases and MRSA infections. Nevertheless, potential adverse factors cannot be ignored when SAL is used in combination with an individual antibacterial agent, such as their mutual influences on physicochemical property leading to incompatibility and the inherent effect of SAL on heart which might be unnecessary in some cases. Moreover, the number and types of pathogenic species used for the evaluation remained to be enlarged, including in depth animal and clinical investigations in the future.
In conclusion, we further demonstrated the vascular disease effective Salvianolate (SAL) was also active on anti-MRSA potentiation of multiple antibacterial agents, which may have the possibility of combinatory therapy with antibacterial agents for the patients of MRSA infection and warrants further pharmacological investigations.
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